GPT and metabolic dysfunction-associated steatohepatitis: In terms of clinical translation, the ACSL4 inhibitor rosiglitazone (4 mg/kg) reduces hepatic 4 - HNE by 72% in an arsenic - induced MASH model, and a phase II clinical trial (NCT04171740) has confirmed that sodium selenate (200 μg/day) normalizes ALT in 47% of patients (Choi et al., 2025).